Carl Hansen

About Carl Hansen

Hansen is cofounder and CEO of AbCellera, which uses a combination of machine learning and proprietary hardware to identify promising antibodies.

These antibodies are used to develop treatments for infectious disease as well as cancer and other conditions.

The underlying technology is based on research Hansen pursued while a professor at the University of British Columbia.

When the Covid-19 pandemic began, his company partnered with Lilly and identified promising treatments against the pandemic.

It took 90 days to find promising candidates, one of which was granted authorization by the FDA in November 2020.